Vanda Pharmaceuticals reported its second-quarter 2025 earnings, revealing a deeper-than-expected net loss and revenue shortfall. The company posted an earnings per share (EPS) of -0.46, missing the forecast of -0.29, representing a negative surprise of 58.62%. Revenues fell short as well, coming in at $52.59 million against the anticipated $55.1 million.
Key Takeaways
- Vanda Pharmaceuticals missed both EPS and revenue forecasts for Q2 2025.
- The stock declined by 9.21% in pre-market trading following the earnings release.
- Fanapt showed strong performance with a 21% revenue increase.
- The company plans to launch six products commercially by 2026.
- Significant net loss of $56.7 million for the first half of 2025.
Company Performance
Vanda Pharmaceuticals experienced mixed results in Q2 2025. While Fanapt’s performance was robust, with a 21% revenue increase, the overall financial results were overshadowed by a net loss of $56.7 million for the first half of the year. The company continues to focus on the psychiatry and neurology markets, expanding its sales force and prescriber engagement efforts.
Financial Highlights
- Revenue: $52.59 million, below the forecast of $55.1 million.
- EPS: -0.46, missing the forecast of -0.29.
- Cash and equivalents: $325.6 million as of June 30, 2025.
Earnings vs. Forecast
Vanda’s EPS of -0.46 fell short of the forecasted -0.29, marking a 58.62% negative surprise. Revenue also missed expectations, coming in at $52.59 million compared to the anticipated $55.1 million, a 4.56% shortfall.
Outlook & Guidance
Vanda projects 2025 revenue to range between $210 million and $250 million, with a year-end cash position expected between $280 million and $320 million. The company anticipates launching six products by 2026, potentially driving future growth.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.